Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium Nitroprusside A Randomized, Double-blind, Placebo-Controlled Trial

Author(s)

Hallak, Jaime E. C. ^{[1, 2]} ; Maia-de-Oliveira, Joao Paulo ^[2] ; Abrao, Joao ^[2] ; Evora, Paulo R. ^[2] ; Zuardi, Antonio W. ^{[1, 2]} ; Crippa, Jose A. S. ^{[1, 2]} ; Belmonte-de-Abreu, Paulo ^{[3, 1]} ; Baker, Glen B. ^{[1, 4, 5]} ; Dursun, Serdar M. ^{[1, 4, 5]}

Affiliation

^[1] Natl Inst Sci & Technol Translat Med, Ribeirao Preto - Brazil

^[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Neurosci & Behav Dept, BR-14049 Ribeirao Preto, SP - Brazil

^[3] Univ Fed Rio Grande do Sul, Dept Psychiat, Porto Alegre, RS - Brazil

^[4] Univ Alberta, Dept Psychiat, Neurochem Res Unit, Edmonton, AB T6G 2G3 - Canada

^[5] Alberta Hosp, Ctr Psychiat Assessment & Therapeut, Alberta Hlth Serv, Edmonton, AB - Canada

• Document type: Journal article
• Source: JAMA PSYCHIATRY; v. 70, n. 7, p. 668-676, JUL 2013.
• Web of Science Citations: 80

Abstract

IMPORTANCE The treatment of schizophrenia remains a challenge, and the currently available antipsychotic drugs are slow acting and produce a number of adverse effects. OBJECTIVE To examine the effectiveness and safety of a single intravenous administration of sodium nitroprusside (0.5 mu g/kg/min for 4 hours) on the positive, negative, anxiety, and depressive symptoms in patients with schizophrenia. DESIGN Single-center, randomized, double-blind, placebo-controlled trial performed from March 9, 2007, to March 12, 2009. SETTING University teaching hospital in Sao Paulo, Brazil. PARTICIPANTS Twenty inpatients aged 19 to 40 years with a diagnosis of schizophrenia who were in the first 5 years of the disease who are taking antipsychotics. INTERVENTION Sodium nitroprusside administration. MAIN OUTCOME MEASURES The 18-item Brief Psychiatric Rating Scale and the negative subscale of the Positive and Negative Syndrome Scale. RESULTS After the infusion of sodium nitroprusside, a rapid (within 4 hours) improvement of symptoms was observed. The placebo and experimental groups had significant differences in the 18-item Brief Psychiatric Rating Scale total score and subscale scores, which persisted for 4 weeks after infusion. CONCLUSIONS The results clearly show a therapeutic effect of sodium nitroprusside. If this drug is approved for routine clinical use in patients with schizophrenia, this discovery will be an important advance in the pharmacologic treatment of this devastating disorder. (AU)

• FAPESP's process: 07/03685-3 - Typical and atypical neurotransmitters in neuropsychiatric disorders
• Grantee: Francisco Silveira Guimaraes
• Support Opportunities: Research Projects - Thematic Grants